AAN

AAN 2025: Tavapadon shows promise as adjunctive therapy for Parkinson disease

April 14, 2025

Tavapadon is an effective and well-tolerated adjunctive therapy to levodopa for Parkinson disease (PD) patients with motor fluctuations, according to findings from a study presented at the annual American Academy of Neurology meeting.

Study details: TEMPO-3 (NCT04542499), a phase 3, placebo-controlled, double-blind study, evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa in adults with PD experiencing motor fluctuations. Participants (N=507, aged 40-80) were randomly assigned to receive tavapadon (5–15 mg once daily) or placebo.

Results: Tavapadon significantly increased total daily ON time without troublesome dyskinesia by 1.1 hours compared with placebo (1.7 hours vs. 0.6 hours; P<0.0001). Additionally, a significant reduction in daily OFF time was observed. The safety profile of tavapadon was consistent with previous trials, with most adverse events being mild to moderate. Ongoing phase 3 trials (TEMPO-1, TEMPO-2, and TEMPO-4) will further evaluate the drug's use as monotherapy in early PD as well as its long-term safety.

Source:

Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease with Motor Fluctuations. Presented at American Academy of Neurology 77th Annual Meeting. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-000258.html